Gastroesophageal adenocarcinoma (GEA) is a global health issue with a high fatality-to-case ratio and a 5-year overall survival that has only slightly improved. High-throughput molecular profiling has uncovered a profound complexity and heterogeneity in GEA biology, which limits considerably the treatment advances. Liquid biopsy with circulating tumor (ct)DNA analysis could elucidate GEA molecular heterogeneity and provide diagnostic, prognostic and predictive information to guide clinical decision-making. However, only a handful of studies have shown positive results for the application of ctDNA analysis in GEA clinical management. As a result, no comprehensive information is available to date on this continuously evolving topic. Here, we discuss the current state of knowledge, along with promises and challenges related to ctDNA analysis in GEA.

ctDNA analysis in the personalized clinical management of gastroesophageal adenocarcinoma: turning hope into reality / M. Salati, K. Venetis, M. Fassan, U. Malapelle, F. Pagni, E. Sajjadi, N. Fusco, M. Ghidini. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - (2021). [Epub ahead of print] [10.2217/fon-2021-0228]

ctDNA analysis in the personalized clinical management of gastroesophageal adenocarcinoma: turning hope into reality

K. Venetis;E. Sajjadi;N. Fusco
;
2021

Abstract

Gastroesophageal adenocarcinoma (GEA) is a global health issue with a high fatality-to-case ratio and a 5-year overall survival that has only slightly improved. High-throughput molecular profiling has uncovered a profound complexity and heterogeneity in GEA biology, which limits considerably the treatment advances. Liquid biopsy with circulating tumor (ct)DNA analysis could elucidate GEA molecular heterogeneity and provide diagnostic, prognostic and predictive information to guide clinical decision-making. However, only a handful of studies have shown positive results for the application of ctDNA analysis in GEA clinical management. As a result, no comprehensive information is available to date on this continuously evolving topic. Here, we discuss the current state of knowledge, along with promises and challenges related to ctDNA analysis in GEA.
biomarker; circulating tumor DNA; ctDNA; efficacy prediction; gastric cancer; gastroesophageal adenocarcinoma; liquid biopsy; minimal residual disease; precision medicine; prognosis
Settore MED/08 - Anatomia Patologica
Settore MED/06 - Oncologia Medica
18-ago-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
[2021] future_oncol_2021_salati.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.51 MB
Formato Adobe PDF
1.51 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/867756
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact